Diagnostic Testing & Technology Report

September 2006

IVD Stocks Steady; Affy Plummets While Inverness Jumps 18%

The 21 stocks in the G-2 Diagnostic Stock Index held steady in the four weeks ended August 4, with 10 stocks up in price, 10 down, and one unchanged. Year to date, the G-2 index is up 13%, while the S&P 500 is up 2% and the Nasdaq is down 5%.

September 2006 - Table of Contents

DTTR September 2006 (full PDF issue)

New Molecular Tests Promise Earlier Cancer Detection

Ventana Medical Systems to Buy Vision Systems for $346M

Affy to Launch Million-SNP Chip

Prodesse Makes the Most of Growing Demand for ASRs

Abbott Sees Growth in Molecular and Point-of-Care, Gets Regulatory Nods

New FDA Task Force to Tackle Tiny World of Nanotech

From Biopsy to Base Pairs: New Molecular Tests Promise Earlier Cancer Detection

Research Drives Comprehensive Molecular Testing at City of Hope Lab

HemoCue Develops Point-of-Care WBC

FDA Clearances for Sysmex Hematology Analyzers

Gene Logic Trims Slumping Genomics Division and Teams With FDA

Dade Behring Expands Drug Testing Portfolio

With Revenues Soaring, Chembio Submits CLIA Waiver Applications

IVD Stocks Steady; Affy Plummets While Inverness Jumps 18%

See You at Lab Institute!

Diagnostic Testing & Technology Report is part of...

Focus Areas	Product Group
G2 Reports Medical Lab Management	Newsletters